Exploiting HIV’s Weaknesses to Develop Effective Vaccines

EU-funded researchers have made significant progress in identifying promising pathways that could lead them towards developing an HIV vaccine.

Photovoltaic, hydrogen mobility, genetic codes, wastewater treatment, Earthquake Defences, food waste, plastic pollution, Breast Cancer, renewable resources, energy self-sufficient, cancer, Infectious Disease in Dogs, Printed Solar Cell, chronic diseases, Radical Aircraft Engine, Infrared Sensor, Mummifying, bacterial and viral infection, steel waste gases, Hydrogen-Powered Mobility, Gene cluster identification, Equipment Waste, plant cells, biodegradable materials, climate change, biomedical devices, Stretchable Smart Sensor, brain cells, interstitium, Mediterranean diet, Bat DNA, graphene, global warming, infectious disease, INTEGRA , cancer, Huntington, man flu, black hole, Carbon dioxide, genes, Alzheimer, Brain-computer interfaces, graphene, immune system, topology, climate change, Twin Embryos, blue brain, climate change, human genome, mature B cell neoplasia, artificial iris, autonomous robot, chemotherapy, tidal energy, Nanomedicine, ecosystem, Mycotoxins, obesity, methylisation, deep drilling, brain scans, volcanic gas, biocatalyst enzymes, earthquakes, detectors, robotics, asthma sufferers, infrastructure, olive trees, solar energy, satellites, olive oil, robotic arms, zika virus, locked-in state, digital detox, climate change, climate, stroke, The new production method was developed by engineers at the University of Exeter. It consists in creating entire device arrays directly on the copper substrates used for the commercial production of graphene, after which complete and fully-functional devices can be transferred to a substrate of choice. This process has been demonstrated by producing a flexible and completely transparent graphene oxide-based humidity sensor. Not only does this device outperform currently-available commercial sensors, but it’s also cheap and easy to produce using common wafer-scale or roll-to-roll manufacturing techniques. ‘The conventional way of producing devices using graphene can be time-consuming, intricate and expensive and involves many process steps including graphene growth, film transfer, lithographic patterning and metal contact deposition,’ explains Prof David Wright from Exeter's Engineering department. ‘Our new approach is much simpler and has the very real potential to open up the use of cheap-to-produce graphene devices for a host of important applications from gas and bio-medical sensors to touch-screen displays.’ One of team’s main objectives was to increase the range of surfaces that graphene devices can be put on. Whilst the demonstrated humidity sensor was integrated in a plasdinosaur, dieting, coral, dengue epidemics, vaccines, thermal energy, artificial intelligence, Cloudlightning, Memristors, Sensory Tool, HIV, autonomous robot, offshore renewable energy, Wearable robots, processors, Artificial, climate, plasmons, Antarctica’s ice, cryogenic preservation

Around 6 300 people a day are infected by HIV, the virus that ultimately causes AIDS, whilst over 25 million people have so far died overall. Finding a vaccine has been the focal point of HIV research since the 1980s. Although this remains elusive, the success of a recent study suggests that scientists are on the right path.

Part-funded through the ERC-funded SHEV project, the study, recently published in the journal ‘Cell Reports’, has identified a key vulnerability in the HIV molecule that could one day be targeted by an effective vaccine. Researchers are also confident that targeting a virus’s precise molecular structure – in order to prompt the immune system to produce specific antibodies – could also be applied to efforts to fight other viruses, such as influenza and Ebola viruses.

The key is that every virus has a signature structure. Understanding the structure of HIV has enabled scientists to gain a better idea of exactly where HIV is vulnerable to infection-blocking antibodies. This is highly significant, because a major problem facing scientists has been the fact that HIV generally conceals vulnerable sites under a dense layer of sugars and fast-mutating parts. This is one reason why the virus has proven so difficult to neutralise; much of the body’s antibody response to infection is directed against fast-mutating parts that render the body’s response useless.

A major step forward was the discovery of random holes in HIV’s protective outer shell of glycan molecules in the 1990s. Although scientists were initially unsure if antibodies could target these holes, this study has now confirmed that these holes could indeed be viable targets for antibodies, and thus play a crucial role in the design of an HIV vaccine.

The findings build on work pioneered at Cornell, The Scripps Research Institute (TSRI) and the Academisch Medisch Centrum in Amsterdam, which coordinated the SHEV project. A stabilised version of an important HIV protein – called the envelope glycoprotein (Env) trimer – was designed in order to encourage rabbits to produce antibodies against the virus.

The scientists then examined where the antibodies bound to the virus, revealing HIV’s vulnerabilities. They found that the antibodies did indeed target holes in the glycan shield of this protein, opening the door to possible future vaccines that encourage the immune system to create hole-targeting antibodies.

While the SHEV project is due for completion at the end of 2016 EU-funded research in this field will continue. A key focus will be on evaluating possible vaccine candidates, and understanding the immune response induced by these vaccines. Much of this research will be financed by the EU’s European AIDS Vaccine Initiative (EAVI2020), which brings together leading HIV researchers from public organisations and biotech companies from across the world.

The ultimate goal is to develop novel candidate vaccines that can be taken through to human trials within five years and provide a platform for discovering new vaccine candidates. The development of a protective vaccine remains the most attractive option for halting the global spread of HIV; around 34 million people are currently living with the virus.

Source: Based on information from CORDIS.